Indivumed

What Indivumed does

Indivumed is a Hamburg, Germany-based precision oncology company that operates an integrated platform for cancer drug discovery and development, founded in 2002 and operating as Indivumed GmbH with 51–100 employees. The company's central asset is IndivuType, a proprietary multi-omics and clinical database built on 20+ years of pre-analytically controlled tumor and normal tissue samples paired with comprehensive clinical and follow-up data, covering genomics, transcriptomics, proteomics, and metabolomics. On top of this data layer, Indivumed applies AI-powered biomathematical tools — including graph analytics and a branded AI analytics platform (Onco AI-Med) — to identify novel therapeutic targets, and uses proprietary patient-derived 2D and 3D tumor models for target validation, with a stated focus on colorectal, pancreatic, lung, and breast cancers.

The commercial offering is structured as a tiered service portfolio: Target Discovery Services (multi-omics + graph analytics), Target Validation Services (patient-derived cellular models), and Therapeutic Development Services (progressing small and large molecules toward IND and beyond), supported by an expanding CRC therapeutic pipeline. Indivumed operates a B2B enterprise sales model targeting pharmaceutical and biotech companies and academic medical centers, generating revenue through R&D partnerships, co-development arrangements, and licensing rather than disclosed product pricing. Named institutional partners include the Wilmot Cancer Institute at the University of Rochester Medical Center; the company also references a global clinical network for sample acquisition and serves customers across EMEA and North America.

Capital structure is private, with a single disclosed financing event — approximately $47.7M from the European Investment Bank in January 2018 — supporting the long-horizon sample collection and platform build. The senior leadership team includes Founder Prof. Dr. Hartmut Juhl, CEO Andrew Deubler, CFO/COO Michael Gutsmann, CIO Frank Clausen, Global CMO Ronald Carter, and Chief Business Officer / Head of IndivuType Business Unit Roald Forsberg, signaling a deliberate build-out of commercial and medical leadership alongside the scientific core.

Name

Indivumed

Legal name

Indivumed GmbH

Website

https://indivumed.com

Company type

Private

Founded year

2002

Operating status

Operating

Headcount range

51–100 employees

Short description

Indivumed is a Hamburg-based precision oncology company that combines a proprietary multi-omics database (IndivuType) of 20+ years of pre-analytically controlled tumor samples, patient-derived 2D/3D tumor models, and AI analytics to discover and validate novel cancer therapeutics for pharmaceutical, biotech, and academic partners.

Ownership category

akta.pro rank

Product category

Precision Oncology Drug Discovery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

akta.pro secondary industries

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

Keywords

• Precision oncology services
• Multi-omics database
• Cancer drug discovery
• Target validation
• Patient-derived models

Headquarters

HQ city

Hamburg

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Indivumed operates an integrated precision oncology R&D platform for cancer drug discovery and development. It combines a proprietary multi-omics and clinical database (IndivuType) built from 20+ years of pre-analytically controlled tumor and normal tissue samples with AI-powered biomathematical tools for target discovery, patient-derived 2D and 3D tumor models for target validation, and downstream therapeutic development progressing small and large molecules toward IND. The company serves pharmaceutical, biotech, and academic partners through R&D collaborations and licensing arrangements.

Product overview

Indivumed is a precision oncology company offering an integrated platform for cancer drug discovery and development. The core offering centers on IndivuType Database, a proprietary multi-omics and clinical database with over 20 years of pre-analytically controlled tumor samples. This is complemented by Target Discovery Services using graph analytics and AI tools, Target Validation Services utilizing patient-derived 2D and 3D tumor models, and Therapeutic Development Services progressing molecules toward IND. The company also maintains a growing CRC (colorectal cancer) pipeline of novel therapeutic targets.

Differentiator

Problem solved

Functional benefit

Brands

• IndivuType: A proprietary multi-omics and clinical database containing pre-analytically controlled tumor and normal tissue samples combined with comprehensive clinical and follow-up data.
• Onco AI-Med

Products and services

• IndivuType Database A highly standardized, proprietary multi-omics and clinical database containing pre-analytically controlled tumor and normal tissue samples combined with comprehensive clinical and follow-up data, reflecting the molecular reality of cancer at an unparalleled level. Used to support target discovery and validation efforts for pharma, biotech, and academic partners.
• Target Discovery Services Discovery services based on comprehensive multi-omics and clinical data using graph analytics and AI-powered biomathematical tools to yield innovative target candidates for cancer therapeutics. Targeted at pharmaceutical and biotech partners engaged in oncology drug discovery.
• Target Validation Services In-depth target validation using cellular models derived from original patient cohorts, including proprietary patient-derived 2D and 3D tumor models for reliable target characterization. For pharma, biotech, and academic partners seeking physiologically relevant validation systems.
• Therapeutic Development Services Cancer drug discovery and development services that progress small and large molecules along the drug discovery and development pipeline toward IND and beyond. Targeted at pharmaceutical and biotech companies seeking to advance cancer therapeutic candidates.
• Patient-Derived Tumor Models Proprietary, well-characterized 2D and 3D tumor models derived from original patient cohorts that closely represent disease characteristics. Used for reliable target validation and drug profiling by pharma, biotech, and academic partners.

Quantifiable outcome

• Expanding CRC (colorectal cancer) pipeline of therapeutically novel targets demonstrates tangible results from unique approach

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Partnerships

One partnership is on record.

• Wilmot Cancer Institute at University of Rochester Medical CentercoreStrategic or Co-development Partner · 10 December 2025Indivumed and the Wilmot Cancer Institute at the University of Rochester Medical Center announced an expanded research collaboration focused on advanced stages of solid cancers such as colorectal, pancreatic, lung, and breast cancer. The partnership aims to leverage tissue and clinical data to develop patient-derived tumor models and identify new therapeutics and biomarkers using AI-powered data analytics. The collaboration may expand to other cancer types in the future.

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Direct peers

• Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput biology with machine learning across multiple therapeutic areas including oncology. Directly comparable in the AI/biologic drug discovery platform category and competes for the same enterprise pharma partnership dollars.
• Exscientia: AI-driven precision medicine company that designs novel drug candidates using its platform and has active oncology programs. Competes head-to-head with Indivumed for pharma AI-discovery partnerships and shares the same end-to-end discovery-to-development thesis.
• Insitro: Machine learning-driven drug discovery company combining induced pluripotent stem cell biology, genomics, and ML. Closely comparable in combining patient-derived biology with AI for target ID and validation in oncology and other indications.
• Schrödinger: Physics-based computational platform for molecular design and predictive analytics used by pharma for hit identification and lead optimization. A direct peer in the AI/ML drug discovery tools and services space, including oncology applications.
• Caris Life Sciences: Molecular science and AI company offering multi-omics tumor profiling (DNA, RNA, protein), patient-derived models, and pharma partnership services. Closely aligned with Indivumed's combination of multi-omics + AI + patient-derived biology for oncology R&D.
• Personalis: Genomics and AI company providing tumor molecular profiling and immuno-oncology biomarker analytics, including patient-derived data assets used to support pharma oncology programs. Comparable in the multi-omics + AI oncology data space.
• Owkin: AI-precision medicine company combining federated patient data from academic centers with ML models for oncology target discovery and drug development. Directly comparable in the AI + multi-omics + academic-clinical-network model Indivumed uses.
• Champions Oncology: Provider of patient-derived xenograft (PDX) and tumor models used by pharma for oncology drug validation and biomarker discovery. Closely comparable in the patient-derived tumor model business that underpins Indivumed's target validation offering.

Broad incumbents

• Tempus AI: Large precision medicine company that combines multi-omics patient data with AI to support oncology drug development and clinical decision support. Operates at much larger scale and broader scope than Indivumed but in the same data-driven oncology discovery space.
• Foundation Medicine: Molecular profiling company providing comprehensive genomic profiling of tumors to support therapy selection and pharmaceutical R&D. Comparable in combining deep molecular tumor data with pharma/biotech commercial channels for oncology drug development.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/2002-indivumed
• Facebookfacebook.com/1363478963746276

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Indivumed